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Objective: Develop a consensus for the nomenclature and definition of adrenal histopathologic 2 
features in unilateral primary aldosteronism (PA) 3 
Context: Unilateral PA is the most common surgically-treated form of hypertension. Morphologic 4 
examination combined with CYP11B2 (aldosterone synthase) immunostaining reveals diverse 5 
histopathologic features of lesions in the resected adrenals.  6 
Patients and Methods: Surgically removed adrenals (n= 37) from 90 patients operated from 2015 7 
to 2018 in Munich, Germany, were selected to represent the broad histologic spectrum of 8 
unilateral PA. Five pathologists (Group 1 from Germany, Italy and Japan) evaluated the 9 
histopathology of haematoxylin-eosin and CYP11B2 immunostained sections and a consensus was 10 
established to define the identifiable features. The consensus was subsequently used by six 11 
additional pathologists (Group 2 from Australia, Brazil, Canada, Japan, UK, USA) for the 12 
assessment of all adrenals with disagreement for histopathologic diagnoses among group 1 13 
pathologists. 14 
Results: Consensus was achieved to define histopathologic features associated with PA. Use of 15 
CYP11B2 immunostaining resulted in a change of the original haematoxylin-eosin morphology-16 
driven diagnosis in 5 (14%) of 37 cases. Using the consensus criteria, group 2 pathologists agreed 17 
for the evaluation of 11 of the 12 cases of disagreement among group 1 pathologists.  18 
Conclusion: The HISTALDO (histopathology of primary aldosteronism) consensus is useful to 19 
standardize nomenclature and achieve consistency among pathologists for the histopathologic 20 
diagnosis of unilateral PA. CYP11B2 immunohistochemistry should be incorporated into the 21 









Primary aldosteronism (PA) is characterized by hypertension and aldosterone overproduction 27 
relative to a suppressed renin-angiotensin system. The main causes of PA are a unilateral 28 
aldosterone-producing adenoma (APA) or bilateral adrenal cortical hyperplasia. Other causes 29 
could include unilateral adrenal cortical hyperplasia and very rarely, an aldosterone-producing 30 
adrenocortical carcinoma (1). Unilateral forms of PA are mainly treated by laparoscopic 31 
adrenalectomy of the overactive gland in contrast to pharmacotherapy with mineralocorticoid 32 
receptor antagonists for bilateral forms (2).  33 
Aldosterone is produced in the zona glomerulosa (ZG) of the adrenal cortex by common enzymes 34 
of all three adrenocortical layers and a specific enzyme of the ZG called aldosterone synthase 35 
(CYP11B2, cytochrome P450 family 11, subfamily B, member 2). CYP11B2 displays a high level 36 
(93%) of amino acid sequence similarity to 11E-hydroxylase (CYP11B1, cytochrome P450 family 11, 37 
subfamily B, member 1) which produces cortisol from 11-deoxycortisol located only in the zona 38 
fasciculata (3). Haematoxylin-eosin (HE) staining differentiates the relatively small and compact 39 
appearance of ZG cells from the larger, lipid-rich and clear cell features of the zona fasciculata (4). 40 
Adrenocortical tumours of patients with PA are composed of clear (lipid rich) or compact 41 
(eosinophilic) cells or a mixture of both (4-6). The variation in cytomorphology is associated with 42 
somatic aldosterone-driver mutations which are prevalent in these tumours (7-9). 43 
The generation and availability of specific monoclonal antibodies to CYP11B2 and CYP11B1 44 
represented a major advance in understanding the pathophysiology of PA (10). Visualization of the 45 
localization of CYP11B2 in resected adrenals identifies the potential source of aldosterone excess. 46 
CYP11B2 immunohistochemistry (IHC) is widely used in scientific studies to examine the functional 47 
morphology of normal and pathological adrenals (11-14) and occasionally in surgical pathology for 48 
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interpretation of the adrenal histology of the resected gland (15). These studies demonstrated the 49 
highly variable histopathologic features of surgically resected adrenals from patients with 50 
unilateral PA. The classical solitary APA (with homogeneous or heterogeneous CYP11B2 51 
immunoreactivity) is often associated with a hyperplastic ZG negative for CYP11B2- 52 
immunoreactivity in the same adrenal. Because an atrophic ZG would be expected in the context 53 
of a suppressed renin-angiotensin system, this is referred to as paradoxical hyperplasia (16). Other 54 
features have been described including multiple macro or micronodules with CYP11B2 positive 55 
immunostaining or diffuse hyperplasia (17). Much focus has centered on relatively small 56 
micronodules of cells beneath the adrenal capsule with marked CYP11B2 immunoreactivity, 57 
usually referred to as aldosterone-producing cell clusters but also as micronodular hyperplasia, 58 
foci, or cell nests. These features are present in normal adrenals as well as in the same adrenal as 59 
an APA or in adrenals without an adenoma from patients operated for both unilateral and bilateral 60 
PA (8, 13, 14, 18-21).  61 
The objectives of this study were to establish consensus among pathologists toward the 62 
standardization of nomenclature and definition of adrenal histopathologic features detected in 63 
specimens from unilateral PA. We hypothesized that using a uniform terminology and defined 64 
criteria should improve consistency and reproducibility of the histopathologic diagnosis of 65 
unilateral PA and help classify the likely pathophysiologic source of aldosterone excess.  66 
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Methods: 67 
The study comprised 3 phases: (I) assessment of the utility of CYP11B2 IHC by a first group of 68 
pathologists (from Germany, Italy, and Japan); (II) identification of histopathologic features 69 
requiring uniform nomenclature and definition, and consensus criteria building for 70 
recommendations; (III) validation of recommendations by histologic consensus-based evaluation 71 
of a subset of adrenals by a second group of pathologists with a diverse geographical distribution 72 
(Australia, Brazil, Canada, Japan, UK, and USA) (Figure 1). 73 
Patient samples 74 
The study included 37 patients diagnosed with unilateral PA and treated at Klinikum der 75 
Universität München, LMU München, Germany in accordance with the Endocrine Society 76 
Guideline (2). Unilateral forms of PA were identified by adrenal venous sampling and treated by 77 
total laparoscopic adrenalectomy according to criteria used in the Munich centre (22).   78 
Catheterization of the right adrenal vein was unsuccessful in 3 cases. These 3 patients all 79 
presented with a florid phenotype including hypokalaemia. Two cases displayed a contralateral 80 
ratio less than 0.8 (where contralateral ratio is defined as the aldosterone/cortisol concentration 81 
ratio of the non-dominant adrenal vein divided by the aldosterone/cortisol concentration ratio of 82 
a peripheral vein) which may indicate that the source of aldosterone production was the adrenal 83 
contralateral to the cannulated gland. In one case, this was also consistent with computer 84 
tomography findings of an adrenocortical nodule in the left gland and a normal right gland. The 85 
third patient was 42 years-old, with hypertension since age 23 and had a unilateral left nodule at 86 
computed tomography imaging. In all 3 cases, the post-surgical evaluation demonstrated a 87 
complete biochemical remission indicating that the localisation of unilateral disease was correct.  88 
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The 37 adrenal specimens were selected from 90 consecutively adrenalectomized patients for 89 
unilateral PA over a four-year period from 2015 to 2018. Surgical handling and processing of the 90 
resected adrenals was according to standard pathology procedures (23). Whole adrenals were 91 
removed by laparoscopic adrenalectomy. All resected adrenals were prospectively sectioned and 92 
stained for HE and CYP11B2 IHC for multiple blocks from the same adrenal according to routine 93 
practice in the Munich centre. Sample inclusion criteria was based on HE staining and CYP11B2 IHC 94 
of the paraffin-embedded adrenals to encompass the entire adrenal pathology spectrum in this 95 
cohort over the four-year period and was enriched for unusual cases which pathologists may 96 
encounter in this disease (assessed by T Knösel, CE Gomez-Sanchez, and TA Williams).  97 
Written informed consent for the scientific study of adrenal specimens (including genotype 98 
analysis and histopathology) and use of patient data was approved by the local ethics committee.  99 
Evaluation of the utility of CYP11B2 immunohistochemistry  100 
Whole slide images were created by scanning the complete histologic slide to produce high-101 
resolution digital files of the HE and CYP11B2 immunostained sections. Images were navigated 102 
using Aperio ImageScope software. The utility of CYP11B2 IHC was evaluated by comparing two 103 
rounds of adrenal assessment: with HE staining alone (phase I, round A) and with the additional 104 
examination of CYP11B2 IHC (phase I, round B) (Figure 1). The pathologists were blinded to the 105 
CYP11B2 IHC during the first-round evaluation of HE slides.  106 
In round A, whole slide images stained with HE were independently evaluated by five pathologists 107 
(Group 1 pathologists: H. Sasano [Sendai, Japan], W. Saeger [Hamburg, Germany], M. Papotti and 108 
I. Castellano [Torino, Italy], and T. Knösel [Munich, Germany]) and examined for histopathologic 109 
findings of “classical” (solitary well circumscribed APA) or “non-classical” (absence of an APA) 110 
unilateral PA. Evaluations were returned to the core group (CE Gomez-Sanchez, WE Rainey, M 111 
 8 
Reincke, TA Williams) before round B in which the same 37 adrenals were examined by group 1 112 
pathologists based on both HE staining and CYP11B2 IHC. 113 
Histopathologic features of these adrenal specimens were identified for the development of 114 
consensus recommendations from the histopathologic assessments of group 1 pathologists by the 115 
core group. The histologic findings referred to as classical or non-classical unilateral PA based on 116 
HE alone or with HE and CYP11B2 immunostaining were then compared to assess the utility of 117 
CYP11B2 IHC.  118 
Assessment of agreement level between group 1 pathologists 119 
Agreement between pathologists for the assessment of each adrenal was defined when four or 120 
more group 1 pathologists (n=6) reached the same histopathologic diagnosis of classical unilateral 121 
PA or non-classical. Cases with disagreement were used for the validation phase by group 2 122 
pathologists. 123 
Consensus building for nomenclature and definition of features 124 
To achieve definitions for specific histopathologic features in the adrenals with PA, group 1 125 
pathologists responded to an open questionnaire requesting criteria for the differentiation 126 
between CYP11B2 positive lesions identified from their assessments. Putative definitions were 127 
derived from responses and feedback from expert clinicians in PA and adrenal experts was 128 
requested (CE Gomez-Sanchez, JWM Lenders, P Mulatero, WE Rainey). A dichotomous 129 
questionnaire to assess agreement or disagreement with the proposed criteria was sent to group 130 
1 pathologists with comments from clinicians and adrenal experts.  131 
A subsequent face-to-face meeting for the discussion of all nomenclature and histopathologic 132 
criteria of features was held in Munich, Germany (Medizinische Klinik und Poliklinik IV, Klinikum 133 
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der Universität München, LMU München) on 13th October 2019. The core group (CE Gomez-134 
Sanchez, WE Rainey, M Reincke, TA Williams), group 1 pathologists (I Castellano, T Knösel, M 135 
Papotti, W Saeger, H Sasano), clinical advisors (JWM Lenders, P Mulatero) were all in attendance.  136 
Validation of consensus 137 
The consensus criteria were subsequently validated by a group of six additional pathologists 138 
(group 2 pathologists) selected to cover a wide geographical distribution over five continents (TJ 139 
Giordano [Ann Arbor, USA], AK Lam [Gold Coast, Australia], A Marker [Cambridge, UK], O Mete 140 
[Toronto, Canada], Y. Yamazaki [Sendai, Japan], MC Nogueira Zerbini [Sao Paolo, Brazil]). Group 2 141 
pathologists were asked to evaluate whole slide images of matched HE and CYP11B2 142 
immunostained slides from 18 of the original set of 37 adrenals evaluated by group 1 pathologists. 143 
The 18 adrenals comprised all 12 adrenals for which group 1 pathologists showed disagreement 144 
and 6 adrenals for which the Group 1 pathologists had reached agreement (3 cases of agreement 145 
for histopathologic findings of “classical” unilateral PA; 3 cases of agreement for “non-classical” 146 
unilateral PA).  147 
The pathologists involved in this study had a special interest in adrenal pathology, but for some of 148 
them, the adrenal was not their primary research interest. All pathologists were blinded to the 149 
others’ diagnoses. 150 
Statistical analyses 151 
Unadjusted analyses were performed using IBM SPSS Statistics version 22.0. Quantitative normally 152 
distributed variables are shown as means with SDs; quantitative non-normally distributed 153 
variables are given as medians and IQRs. Categorical variables are shown as absolute numbers and 154 
percentages. A student t-test was used to compare quantitative normally distributed variables. A 155 
Mann-Whitney U test was applied for the analysis of group differences of quantitative non-156 
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normally distributed variables and a Chi-square or Fisher´s exact tests for categorical variables. 157 
The absolute number and proportion of patients in each post-surgical outcome category 158 
(complete, partial and absent clinical and biochemical success at 6-12 months after surgery) were 159 
assessed by the PASO criteria (24). Patients classified with absent biochemical success after 160 
surgery all failed to suppress aldosterone production below 277 pmol/L (10 ng/dL) with a post-161 
surgical saline infusion confirmatory test (2).  162 
 
Results: 163 
Supplemental tables and figures can be downloaded directly at: 164 
https://github.com/MedIVLMUMunich/HISTALDOconsensus (25). 165 
Phase I - Assessment of adrenalectomy specimens and identification of histopathologic features 166 
requiring uniform nomenclature and definition 167 
With HE-based assessment alone (Phase I, Round A), group 1 pathologists agreed with the 168 
histopathologic diagnosis in 21 (56.8%) of 37 cases, but, disagreed in the remaining 16 (43.2%) 169 
cases. The 21 cases consisted of 18 diagnoses of classical histopathologic findings of unilateral PA, 170 
and the three remaining cases were non-classical histopathologic findings. With the additional 171 
examination of CYP11B2 IHC (Phase I, Round B), disagreement between group 1 pathologists was 172 
reduced from 16 (43.2%) to 12 (32.4%) of 37 cases. The 25 cases with mutual agreement (67.6%) 173 
comprised 16 adrenals with histopathologic findings of classical unilateral disease, and nine non-174 
classical cases (Figure 2). 175 
Comparison of adrenal scoring based on HE staining alone (round A) with assessment including 176 
CYP11B2 IHC (round B, group 1 pathologists) demonstrated that the visualization of CYP11B2 177 
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(aldosterone synthase) resulted in three or more of the five pathologists changing their original 178 
histopathologic diagnosis for five cases (14%). These cases comprised adrenals #10, #11, #14, #19 179 
and #20 (25, Figures S1 and S2).  180 
Histopathologic features derived from the evaluations included the following terminologies: (i) 181 
APA, (ii) non-functioning adenoma, (iii) CYP11B2 positive nodule, (iv) aldosterone-producing cell 182 
clusters, (v) CYP11B2 positive micronodule, (vi) micronodular hyperplasia and (vii) diffuse 183 
hyperplasia. 184 
Phase II - consensus building for recommendations  185 
After two rounds of questionnaires and the face-to-face meeting, unanimous consensus was 186 
reached for recommendations for nomenclature and for the distinction of specific lesions (Table 187 
1). This resulted in the criteria below for the histopathology of unilateral PA. 188 
Aldosterone-producing adenoma: 189 
An APA is a solitary neoplasm of at least 10 mm diameter composed of clear cells, compact 190 
eosinophilic cells, or a mixture of both (26). An APA and a nonfunctioning adenoma are 191 
morphologically similar and cannot be differentiated by HE staining alone. Differentiation is based 192 
on clinical information including functional assessment of aldosterone overproduction by adrenal 193 
venous sampling and histologic findings of CYP11B2 positive immunostaining in tumour cells using 194 
a validated CYP11B2 antibody (10) (Figure 3). Terminology such as “glomerulosa-like” and 195 
“fasciculata-like” should not be used for the description of small compact or lipid-rich cells of an 196 
APA in favour of the correct pathologic description of compact eosinophilic or clear cells in surgical 197 
pathology reports. Macroscopic criteria relating to the colour of the cut surface of the adrenal 198 
specimen and microscopic criteria related to the presence of spironolactone bodies in tumour 199 
cells are unreliable and should not be considered in the diagnosis of APA.  200 
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Aldosterone-producing nodule: 201 
An aldosterone-producing nodule is a CYP11B2 positive lesion of less than 10 mm diameter 202 
composed of clear cells, compact eosinophilic cells, or a mixture of both. An aldosterone-203 
producing nodule and an APA display similar morphology but HE staining can help distinguish the 204 
smaller size of a nodule from an adenoma if the lesion has been sectioned appropriately at its 205 
greatest diameter. Aldosterone-producing nodules often show polarity of CYP11B2 206 
immunostaining with decreasing intensity of immunoreactivity from the outer to the inner part of 207 
the lesion (Figure 3). This contrasts with the CYP11B2 immunoreactivity in most APAs in which a 208 
gradient of CYP11B2-positive staining is absent and replaced by either a homogeneous or a 209 
diffusely heterogeneous pattern of CYP11B2 immunoreactivity throughout the lesion. 210 
Aldosterone-producing micronodule: 211 
An aldosterone-producing micronodule is a CYP11B2 positive lesion measuring less than 10 mm (in 212 
the greatest dimension), located in the outer margin of the subcapsular ZG (Figure 3). An 213 
aldosterone-producing micronodule cannot be distinguished by HE from the surrounding ZG. In 214 
contrast, an aldosterone-producing nodule is morphologically visible with HE staining and can be 215 
located elsewhere within the adrenal cortex. Therefore, both CYP11B2 IHC and HE staining are 216 
needed to distinguish these two lesions. Aldosterone-producing micronodules also often show 217 
polarity of CYP11B2 immunostaining with decreasing intensity of immunoreactivity from the outer 218 
to the inner part of the lesion. There is no evidence that an aldosterone-producing micronodule 219 
can be distinguished from the feature described in the scientific literature as an aldosterone-220 
producing cell cluster. The term “cell cluster” is an unclear term which does not describe the 221 
histology and therefore, “aldosterone-producing cell cluster” should be replaced by the 222 
recommended term of “aldosterone-producing micronodule”. 223 
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Multiple aldosterone-producing nodules or micronodules: 224 
Multiple aldosterone-producing nodules or micronodules are characterized by the separation of 225 
aldosterone-producing nodules or micronodules by histologically normal non-hyperplastic ZG 226 
(Figure 3). The terminology “nodular hyperplasia” or “micronodular hyperplasia” should be 227 
replaced by the recommended terms of “multiple aldosterone-producing nodules” or “multiple 228 
aldosterone-producing micronodules” which describe the histologic features of these lesions more 229 
precisely. When aldosterone-producing nodules and aldosterone-producing micronodules are 230 
found concurrently, the histologic findings should be described as multiple aldosterone-producing 231 
nodules and micronodules. 232 
Aldosterone-producing diffuse hyperplasia: 233 
Aldosterone-producing diffuse hyperplasia is distinguished from multiple aldosterone-producing 234 
micronodules by both cytomorphology and CYP11B2 IHC. Aldosterone-producing diffuse 235 
hyperplasia is the occurrence of a broad and uninterrupted strip of hyperplastic ZG cells with 236 
CYP11B2 positive immunostaining in more than 50% of cells (Figure 3). The term aldosterone-237 
producing diffuse hyperplasia is applied irrespective of the presence of aldosterone-producing 238 
nodules in the same adrenal gland. 239 
Importance of tissue handling and sectioning: 240 
During the face-to-face meeting, tissue handling, and sectioning of surgically removed adrenal 241 
specimens were also discussed. 242 
Pre-analytical conditions affect the results of CYP11B2 IHC and recommendations for tissue 243 
preparation and fixation are the same as described in detail elsewhere (23). Pathology reporting 244 
should follow standard procedures. Histologic diagnosis is more challenging by adrenal resection 245 
in multiple pieces. Surgical removal of the entire adrenal specimen in a single piece including the 246 
 14 
tumour nodule with the attached adrenal cortex with minimal damage is recommended for 247 
improved morphologic assessment. Equatorial and vertical sectioning of adrenal tissue is 248 
recommended because tangential sections may distort the architecture of lesions. Sectioning 249 
should be performed at the greatest lesion diameter to avoid misclassification of an adenoma (at 250 
least 10 mm diameter) as a nodule (less than 10 mm diameter). 251 
The whole surgically resected specimen should be submitted for histopathologic examination to 252 
allow the management of conventional cases with different protocols versus complex cases. Thus, 253 
solitary APAs with classical pathological features can be processed with a limited number of 254 
sections because there is a low risk of missing relevant histological data in the deeper levels of the 255 
paraffin block. Conversely, for more complex specimens, especially those with apparently negative 256 
CYP11B2 immunostaining, analyzing the entire specimen on multiple sectioning maximizes the 257 
possibility of visualizing the culprit lesion with CYP11B2 IHC.  258 
Phase III – validation of consensus 259 
The consensus criteria and recommendations (Panel 1) were provided to group 2 pathologists for 260 
the evaluation of whole slide images generated from HE stained and CYP11B2 immunostaining of 261 
all 12 adrenals with disagreement for histopathologic assessment between group 1 pathologists as 262 
well as six additional adrenals with agreement (Figure 2). Agreement between pathologists was 263 
maintained for these six cases by the group 2 pathologists. In the assessment of the 12 adrenals 264 
with disagreement between group 1 pathologists, using the consensus criteria, at least five of the 265 
six group 2 pathologists agreed for the histopathologic diagnosis of nine adrenals and four 266 
pathologists agreed for the assessment of two of the remaining three adrenals. Disagreement was 267 
maintained for the classification of adrenal #18 as classical versus non-classical unilateral PA (25, 268 
Figure S3). The individual pathologists´ assessments are shown in Table S2 (25). This adrenal was 269 
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resected from a patient with complete biochemical success and partial clinical success after 270 
surgery.  271 
Pathology findings of resected adrenals 272 
Among 24 adrenals categorized as classical histopathology of unilateral PA, 21 had an APA and the 273 
remaining three had an aldosterone-producing cortical nodule (25, Figure S1). The non-tumorous 274 
adrenal cortex adjacent to the APA frequently displayed paradoxical ZG hyperplasia with negative 275 
CYP11B2 immunostaining, aldosterone-producing micronodules or nodules or aldosterone-276 
producing diffuse hyperplasia (25, Figure S1).  277 
Among 12 adrenals with features of non-classical unilateral PA, three had aldosterone-producing 278 
diffuse hyperplasia (adrenals #4, #9, and #29), two showed a nonfunctioning cortical adenoma 279 
with aldosterone-producing diffuse hyperplasia in the adjacent cortex (#8, and #19), and the 280 
remaining seven cases had multiple aldosterone-producing nodules (#5, #6, #21, and #31), 281 
aldosterone-producing micronodules (#30) or a mixed phenotype of aldosterone-producing 282 
nodules and aldosterone-producing micronodules (#7 and #33) (25, Table S1, Figure S2). 283 
Clinical parameters stratified by histopathologic diagnosis 284 
Unadjusted clinical data at baseline and follow-up are shown for all patients with inter-pathologist 285 
agreement with respect to histopathologic findings (Table 2). The histopathologic diagnosis of 286 
classical unilateral PA was identified in 24 of the 36 cases and a non-classical histopathology was 287 
assigned to 12 cases (Figure 2). There was no agreement among pathologists for the 288 
histopathology of the remaining case (25, Figure S3). Therefore, from pathology assessments, this 289 
adrenal could not be categorized as either classical or non-classical unilateral PA and was excluded 290 
from the descriptive statistical analysis (Table 2). 291 
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Patients with histopathologic findings of non-classical unilateral PA displayed a longer known 292 
duration of hypertension compared with the classical group (114 months [48 to 176] versus 11 293 
months [3 to 100], p= 0.010) and a smaller nodule size at pathology (6 mm [3 to 10] versus 12 mm 294 
[8 to 20], p= 0.019). The lateralization index (a ratio indicating the level of asymmetry of 295 
aldosterone production from the adrenal glands) was also lower in the non-classical compared 296 
with the classical group (5.8 [4.4 to 11.5] versus 13.9 [6.7 to 36.2], p= 0.048). The serum potassium 297 
ion concentration at baseline was relatively higher in the non-classical compared with the classical 298 
group (3.4 mmol/L ± 0.62 versus 3.0 ± 0.43), but lower at 6-12 months after surgery (3.9 mmol/L ± 299 
0.42 versus 4.4 mmol/L ± 0.41, p= 0.006). During the post-surgical follow-up, the non-classical 300 
group also displayed a higher aldosterone-to-renin ratio (used as a screening test for PA) than the 301 
classical group (48 [28 to 115] versus 21 [6 to 32], p= 0.006).  302 
Post-surgical follow-up data was available for 34 of the 36 patients with agreement among 303 
pathologists for the histopathologic assessment. The two patients with missing follow-up data 304 
were included because the adrenals were considered of interest for histopathologic findings of a 305 
principal CYP11B2 positive lesion with additional CYP11B2 positive lesions of different forms and 306 
dimensions in the adjacent cortex.  307 
The assessment of post-surgical outcomes using the PASO criteria (24) demonstrated no 308 
significant differences in clinical outcomes between the two groups (p= 0.286) but biochemical 309 
outcomes were different (p= 0.009 for group difference). Complete biochemical success 310 
(biochemical remission) was achieved in 81.9% (18 of 22) of patients with classical histopathologic 311 
findings of unilateral PA compared with 33.3% (4 of 12) of patients in the non-classical group (p= 312 
0.008) (Table 2). A higher proportion of patients with a non-classical histopathology of unilateral 313 
PA displayed absent biochemical success after surgery (41.7%, 5 of 12 patients) than patients in 314 
the classical group (4.5%, 1 of 22 patients, p= 0.014) (Table 2).  315 
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Discussion: 316 
This study developed consensus recommendations for the nomenclature and definitions of the 317 
histopathologic features associated with unilateral PA. The consensus was built and validated with 318 
the participation of an international group of expert pathologists from five continents (Asia, 319 
Australia, Europe, North America, and South America) and contributed to an improved consistency 320 
among pathologists for the histopathologic diagnosis of this disease. 321 
The pathologic examination of the adrenalectomy specimens from patients with unilateral PA 322 
identifies the morphologic changes associated with the disorder. IHC for CYP11B2 (aldosterone 323 
synthase), which catalyzes the terminal, and rate limiting steps of aldosterone biosynthesis, is not 324 
widely used in clinical pathology but helps visualize the most likely site of aldosterone production 325 
(10, 11, 27). For instance, in an early study in which a patient´s adrenal was subjected to CYP11B2 326 
IHC staining, aldosterone-producing micronodules were the presumed source of aldosterone 327 
overproduction rather than the primary cortical macronodule which was negative for CYP11B2 328 
(16). This finding is clinically relevant because an adrenal-sparing surgical approach, guided by 329 
computed tomography imaging data rather than total adrenalectomy, may not necessarily remove 330 
the culprit lesion. 331 
Studies with CYP11B2 immunostaining on normal and pathological adrenal glands have also 332 
demonstrated the frequent presence of aldosterone-producing micronodules (18, 19). These 333 
micronodules are widely referred to as aldosterone-producing cell clusters but the term “cell 334 
cluster” is ambiguous and not used in pathology and therefore should be replaced with 335 
aldosterone-producing micronodule. Aldosterone-producing micronodules have also been 336 
reported in adrenals without an APA from patients with preoperative unilateral PA (13), in a small 337 
series of adrenals from patients with presurgical bilateral PA (21) and in normal adrenals from 338 
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kidney donors (20). The aldosterone-producing micronodules in the adrenals from these different 339 
groups of patients and individuals appear to differ by the prevalence of mutations in the genes 340 
implicated in constitutive aldosterone production (primarily in CACNA1D encoding the calcium 341 
channel Cav1.3), by their size or relative number of aldosterone-producing micronodules per 342 
adrenal (20, 21). In addition, a subset of APMs display convergent in situ metabolic profiles to 343 
APAs (28) and may represent the progression of APMs to APAs (29).  344 
The current study showed that the evaluation of CYP11B2 immunostaining in addition to routine 345 
morphologic assessment based on HE staining resulted in a change of the original histopathologic 346 
interpretation in 14% of patients. In addition, this approach also highlighted several cases of a 347 
nonfunctional adrenocortical adenoma in association with an aldosterone-producing nodule, 348 
multiple aldosterone-producing micronodules or aldosterone-producing diffuse hyperplasia. These 349 
findings above underscore the utility of CYP11B2 IHC in the diagnostic workup of unilateral PA.  350 
This series also demonstrated an association of histopathology with post-surgical biochemical 351 
outcomes. Around 40% of cases with non-classical histopathologic findings of unilateral PA 352 
(absence of an APA) were associated with post-surgical absent biochemical success (indicating 353 
persistent aldosteronism) compared with under 5% with a classical histopathology of a solitary 354 
APA. Because biochemical outcomes indicate if the presurgical diagnosis of unilateral disease was 355 
accurate, histopathology may compliment biochemical follow-up to provide reassurance that the 356 
clinical diagnosis was correct or highlight patients requiring close post-surgical follow-up (14, 30).  357 
This is also clinically relevant because PA is associated with a high incidence of cardiovascular, 358 
metabolic and renal complications (31) and incomplete treatment is associated with an increased 359 
rate of adverse events (32). 360 
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For the first time since the historical description of adrenocortical pathology in 1985 by Neville and 361 
O’Hare (4), this study provides consensus recommendations to define the various pathologic 362 
findings in adrenals from patients with unilateral PA which include immunohistochemical 363 
evaluation with a CYP11B2 monoclonal antibody available since 2014 (10). 364 
The strengths of our study include the participation of 11 pathologists from five continents to 365 
evaluate the adrenals using stringent criteria to assess agreement for histopathologic diagnoses. In 366 
addition, a sample set of adrenal specimens was assessed covering the broad spectrum of adrenal 367 
histopathology with a wide variety of features. A further strength is the independent assessment 368 
of morphology from CYP11B2 immunostaining which allowed us to assess the utility of functional 369 
immunostaining.  370 
The main limitation of the study in the clinical setting is the inability to provide consensus criteria 371 
for the histopathology of adrenals from patients operated for bilateral PA because these patients 372 
are rarely operated and tissue samples are usually unavailable.   373 
In conclusion, the HISTALDO consensus provides recommendations and criteria for the 374 
histopathologic diagnosis of unilateral PA. We identified the main histologic features associated 375 
with this disease and demonstrated that using a standardized set of criteria improves diagnostic 376 
agreement between pathologists. Our findings demonstrate the relevance of histopathology with 377 
morphologic and IHC evaluation in the clinical management of unilateral PA. Histopathologic 378 
examination of adrenalectomy specimens with CYP11B2 IHC is therefore recommended for all 379 
patients operated for unilateral PA. 380 
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Glossary: 
APA  aldosterone-producing adenoma 
APACC  aldosterone-producing adrenocortical carcinoma  
APDH  aldosterone-producing diffuse hyperplasia  
APM  aldosterone-producing micronodule  
APN  aldosterone-producing nodule  
ARR  aldosterone-to-renin ratio 
BMI   body mass index 
BP  blood pressure 
DDD  defined daily dose 
DRC   direct renin concentration 
HE  haematoxylin-eosin 
IHC  immunohistochemistry 
HTN  hypertension 
MAPM  multiple aldosterone-producing micronodules  
MAPN  multiple aldosterone-producing nodules 
PA  primary aldosteronism 
ZG  zona glomerulosa 
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Figure Legends: 
Figure 1:  HISTALDO consensus procedure 
Paraffin-embedded adrenals were selected from HE staining and CYP11B2 immunohistochemistry to cover 
the wide spectrum of adrenal histopathology observed in surgically-treated patients for unilateral PA (37 of 
90 adrenals). Whole slide images of the 37 HE-stained adrenals were assessed by 5 pathologists (group 1 
pathologists, round A) for histopathology associated with “classical” or “non-classical” unilateral PA. Group 
1 pathologists subsequently assessed the same adrenals based on HE and CYP11B2 (aldosterone synthase) 
immunostaining (round B) to evaluate the utility of CYP11B2 IHC in the diagnostic pathology of unilateral 
PA. Diverse features associated with unilateral PA for the consensus building phase were identified from 
histopathologic findings. Consensus was achieved by two rounds of questionnaires comprising an open 
questionnaire, a dichotomous questionnaire (agree or disagree) and a face-to-face meeting (see Methods 
for further details). The consensus criteria were provided to a group of 6 additional pathologists (group 2 
pathologists) as a guide for HE and CYP11B2 IHC-based examination of 18 of the 37 adrenals assessed by 
the group 1 pathologists. The 18 adrenals comprised 6 adrenals for which group 1 pathologists showed 
agreement (3 cases of agreement for classical and 3 cases of agreement for non-classical histology of 
unilateral PA (25, adrenals #1 to #6) and all 12 adrenals for which group 1 pathologists showed a high level 
of disagreement (25, adrenals #7 to #18).  
 
Figure 2. Agreement between group 1 and group 2 pathologists for the histopathologic diagnosis 
of unilateral primary aldosteronism. 
Agreement was defined as at least 4 of the 5 group 1 pathologists or at least 4 of the 6 group 2 pathologists 
reaching the same histopathologic diagnosis. Classical, indicates “classical” histopathology associated with 
unilateral PA of a solitary APA or APN; non-classical, indicates “non-classical” histopathology of MAPM or 
MAPN (or MAPM and MAPN together) or APDH.  
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Figure 3. Histopathologic features in surgically removed adrenals from patients with unilateral 
primary aldosteronism 
Paraffin-embedded adrenal sections (3 Pm) were processed and stained for haematoxylin-eosin (H&E) and 
immunostained for CYP11B2 (aldosterone synthase) using the mouse monoclonal anti-human CYP11B2 
antibody (clone 17B) (10). APAs are shown with homogeneous (Panel A) and heterogeneous (Panel B) 
CYP11B2 immunostaining. The CYP11B2 positive immunostaining in tumour cells distinguishes an APA from 
a nonfunctioning adenoma (Panel C). APNs (aldosterone-producing nodules) are morphologically visible 
with HE staining (Panel D) whereas APMs (aldosterone-producing micronodules) are morphologically 
indistinct from adjacent adrenocortical cells (Panel E).  








Table 1. HISTALDO consensus for nomenclature and histopathology of adrenal cortical lesions in 
unilateral primary aldosteronism.  
*CYP11B2= aldosterone synthase. CYP11B2 immunostaining must be performed using a well validated 
antibody (10) 
**The histopathologic diagnosis of small lesions requires appropriate tissue sectioning to allow assessment 
of greatest diameter or dimension and to avoid distortion of lesion architecture   
Histopathological entity Abbreviation Definition 
Aldosterone-producing 
adrenocortical carcinoma  
APACC Aldosterone-producing malignant neoplasms, including 
variants, follow the same pathologic criteria of other 
adrenocortical cancers. 
Aldosterone-producing adenoma APA Well circumscribed CYP11B2*-positive solitary neoplasm 
(≥ 10 mm diameter) composed of clear or compact 
eosinophilic cells or both cell types. 
Aldosterone-producing nodule APN CYP11B2-positive lesion (< 10 mm diameter)** 
morphologically visible with haematoxylin-eosin staining.  
An APN often displays a gradient of CYP11B2 
immunostaining decreasing in intensity from the outer to 
the inner part of the lesion.  
Aldosterone-producing micronodule 
(formally known as aldosterone-
producing cell cluster) 
APM CYP11B2-positive lesion (< 10 mm diameter)** composed 
of zona glomerulosa cells located beneath adrenal 
capsule that do not differ in morphology from adjacent 
adrenocortical cells by haematoxylin-eosin staining. An 
APM often displays a gradient of CYP11B2 
immunostaining decreasing in intensity from the outer to 
the inner part of the lesion.  
Multiple aldosterone-producing 
nodules or multiple aldosterone-
producing micronodules (formally 
known as micronodular hyperplasia) 
MAPN or 
MAPM 
Multiple APN or multiple APM located beneath the 
adrenal capsule with intermittent regions of normal zona 




APDH Relatively broad and uninterrupted strip of zona 
glomerulosa cells with more than half of these cells 












Age at surgery (years) 36 49 (13.4) 49 (13.6) 49 (13.6) 0.959 
Sex* (ref. female) 36 20 (55.6%) 13 (54.2%) 7 (58.3%) 0.813 
BMI (kg/m2) 36 26.7 (4.83) 26.5 (4.51) 27.0 (5.62) 0.800 
Known duration of HTN 
(months) 
35 50 (4 to 134) 11 (3 to 100) 114 (48 to 176) 0.010 
Genotype: KCNJ5 mutated 29 12 (41.4%) 11 (50.0%) 1 (14.3%) 0.187 
Largest nodule size at 
pathology (diameter, mm) 
30 9 (7 to 18] 12 (8 to 20) 6 (3 to 10) 0.019 
Clinical parameters at baseline 
Plasma aldosterone 
(pmol/L) 
36 627 (457 to 870) 659 (457 to 922) 567 (409 to 754) 0.518 
DRC (mU/L) 36 3.3 (2.0 to 7.1) 2.2 (2.0 to 7.1) 4.4 (2.0 to 13.8) 0.416 
ARR ([pmol/L]/[mU/L]) 36 162 (71 to 356) 170 (82 to 356) 139 (41 to 355) 0.476 
Lowest serum potassium  
(mmol/L) 
36 3.1 (0.52) 3.0 (0.43) 3.4 (0.62) 0.031 
Systolic BP (mmHg) 36 147 (21.4) 148 (24.1) 147 (15.7) 0.927 
Diastolic BP (mmHg) 36 92 (18.1) 92 (19.8) 93 (14.8) 0.853 
AntiHTN medication 
(defined daily dose) 
36 2.13 (1.00 to 3.88) 2.38 (1.13 to 3.88) 2.00 (0.81 to 3.75) 0.608 
Lateralization index 33 12.9 (5.1 to 27.2) 13.9 (6.7 to 36.2) 5.8 (4.4 to 11.5) 0.048 
Clinical parameters at follow-up  
Plasma aldosterone 
(pmol/L) 
34 323 (183 to 584) 276 (155 to 494) 473 (240 to 1086) 0.058 
DRC (mU/L) 34 14.5 (6.6 to 25.4) 17.0 (9.2 to 28.9) 6.5 (4.4 to 18.4) 0.044 
ARR ([pmol/L]/[mU/L]) 34 28 (8 to 52) 21 (6 to 32) 48 (28 to 115) 0.006 
Lowest serum potassium 
(mmol/L) 
34 4.2 (0.46) 4.4 (0.41) 3.9 (0.42) 0.006 
Systolic BP (mmHg) 34 136 (16.2) 134 (17.2) 140 (14.0) 0.338 
Diastolic BP (mmHg) 34 87 (12.6) 86 (14.2) 88 (9.5) 0.758 
AntiHTN medication 
(defined daily dose) 
34 0.83 (0.00 to 2.13) 0.58 (0.00 to 2.53) 1.00 (0.50 to 1.88) 0.423 
Clinical Outcome         
Complete (n; %) 
Partial (n; %) 












Biochemical Outcome        
Complete (n; %) 
Partial (n; %) 















Table 2. Clinical characteristics of patients stratified by histopathologic findings of classical and 
non-classical unilateral primary aldosteronism 
 
Unadjusted analysis of clinical parameters with data shown as the mean (SD), n (%), or median (IQR). P 
values less than 0.05 were considered significant. Patient data from all cases of agreement between 
pathologists (36 of 37 resected adrenals with 25 cases of agreement between group 1 pathologists and 11 
cases of agreement between group 2 pathologists (Figure 2). The remaining patient with disagreement 
between pathologists was excluded from the analysis. 
 
Classical, indicates “classical” histopathology associated with unilateral PA of a solitary APA or APN; non-
classical, indicates “non-classical” histopathology of MAPM or MAPN (or MAPM and MAPN together) or 
APDH. Adrenal nodule diameter refers to the size of the largest nodule measured at pathology; lowest 
serum potassium refers to the lowest recorded serum potassium ion concentration and antihypertension 
medication is expressed as defined daily dose (DDD) which is the assumed average maintenance dose per 
day for a drug used for its main indication in adults (ATC/DDD Index 2010). The catheterization of the right 
adrenal gland was unsuccessful for three of 36 patients (lateralization indices could not be calculated). 
Follow-up measurements were unavailable for two of the 36 patients. Pairwise differences are shown for 
biochemical outcomes which displayed an overall group difference (p= 0.017). Genotype data was available 
for 29 of the 36 patients: a KCNJ5 mutation positive group (n= 12), and a KCNJ5 mutation negative group 
(n= 17). The latter group comprised those with no mutation detected (n= 13), ATP1A1 mutations (n= 2), a 
CACNA1D mutation, and a PRKACA mutation. Clinical and biochemical outcomes after unilateral 
adrenalectomy were assessed in accordance with the PASO criteria at 6-12 months after surgery (24). 
 
ARR, aldosterone-to-renin ratio; BMI, body mass index; BP, blood pressure; DRC direct renin concentration; 
HTN, hypertension; KCNJ5, potassium inwardly rectifying channel subfamily J member 5; ref., reference. 
*The p-value is for sex in general; **overall p-value for biochemical outcomes= 0.009.  
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